Company news
Cybin, Inc. (NEO:HELP) news
Every Cybin, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Helus Pharma Appoints Regina Donohue as Chief People Officer and Suresh Durgam, M.D., to its Scientific Advisory Board
August 18, 2026
Helus Pharma Reports First Quarter Fiscal 2027 Financial Results and Recent Business Highlights
August 14, 2026
Helus Pharma to Participate at the Canaccord Genuity 46th Annual Growth Conference in Boston
August 10, 2026
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Bio...
August 5, 2026
Helus Pharma Appoints Michael Halstead as Chief Executive Officer
August 3, 2026
Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule
July 21, 2026
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
July 17, 2026
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results
June 29, 2026
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
June 26, 2026
Helus Pharma(TM) Announces Closing of US$50 Million Underwritten Offering
June 25, 2026
Helus Pharma(TM) Announces US$50 Million Underwritten Offering
June 24, 2026
Helus Pharma to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Conference
June 11, 2026
Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York
June 1, 2026
Helus Pharma to Participate at the 29th Annual Milken Institute Global Conference
April 30, 2026
Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health 
April 28, 2026
Helus Pharma Strengthens Scientific Advisory Board with Addition of Dr. Robert Langer and Dr. Stephen Brannan
April 23, 2026
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Condi...
April 20, 2026
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs
April 16, 2026
Helus Pharma Strengthens Executive Team with Appointment of Jill Conwell as Chief People Officer
March 12, 2026
CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions
March 9, 2026
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion
March 5, 2026
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
March 5, 2026
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments
February 27, 2026
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
February 26, 2026
Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity
February 24, 2026
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory C...
February 24, 2026
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder
February 17, 2026
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
February 13, 2026
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
February 10, 2026
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
February 10, 2026
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq
January 5, 2026
Cybin Initiates At-The-Market Equity Program of up to US$100 Million
December 30, 2025
Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
December 19, 2025
KILL Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq
December 18, 2025
Cybin Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights
November 13, 2025
Cybin to Participate in the Jefferies Global Healthcare Conference in London
November 12, 2025
Cybin to Announce Second Quarter Financial Results and Provide Business Update on November 13, 2025
November 6, 2025
Cybin to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
November 5, 2025
Cybin to Participate at the 2025 Milken Institute Future of Health Summit
November 3, 2025
Cybin Announces Closing of $175 Million Registered Direct Offering
October 31, 2025
Cybin Announces $175 Million Registered Direct Offering
October 28, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
October 23, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
September 24, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cybin Inc. - CYBN
September 14, 2025
Ongoing Investigation into Cybin Inc. (CYBN): Contact Levi & Korsinsky About Potential Fraud
September 10, 2025
Cybin to Participate in the Cantor Global Healthcare Conference 2025
September 3, 2025
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
July 1, 2025
A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update
July 8, 2024
Breakthrough Results: Cybin's CYB003 Demonstrates Remarkable Interim Data in Treating Major Depressive Disorder, Achieving Primary Effica...
November 1, 2023